S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
NASDAQ:DNAY

Codex DNA Stock Competitors

$6.41
-0.01 (-0.16%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.22
$6.49
50-Day Range
$6.41
$13.28
52-Week Range
$6.22
$25.70
Volume
33,074 shs
Average Volume
116,844 shs
Market Capitalization
$187.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Codex DNA (NASDAQ:DNAY) Vs. NAUT, EYPT, AKYA, RPID, FLDM, ISO, AXDX, HBIO, TLIS, and PRPO

Should you be buying Codex DNA stock or one of its competitors? The main competitors of Codex DNA include Nautilus Biotechnology (NAUT), EyePoint Pharmaceuticals (EYPT), Akoya Biosciences (AKYA), Rapid Micro Biosystems (RPID), Fluidigm (FLDM), IsoPlexis (ISO), Accelerate Diagnostics (AXDX), Harvard Bioscience (HBIO), Talis Biomedical (TLIS), and Precipio (PRPO). These companies are all part of the "analytical instruments" industry.

Codex DNA vs.

EyePoint Pharmaceuticals (NASDAQ:EYPT) and Codex DNA (NASDAQ:DNAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

74.1% of EyePoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 55.2% of Codex DNA shares are owned by institutional investors. 26.7% of EyePoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Codex DNA has lower revenue, but higher earnings than EyePoint Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EyePoint Pharmaceuticals$34.44 million14.31-$45.39 million-$2.50-5.82
Codex DNAN/AN/AN/AN/AN/A

EyePoint Pharmaceuticals received 414 more outperform votes than Codex DNA when rated by MarketBeat users. Likewise, 71.11% of users gave EyePoint Pharmaceuticals an outperform vote while only 70.00% of users gave Codex DNA an outperform vote.

CompanyUnderperformOutperform
EyePoint PharmaceuticalsOutperform Votes
421
71.11%
Underperform Votes
171
28.89%
Codex DNAOutperform Votes
7
70.00%
Underperform Votes
3
30.00%

In the previous week, EyePoint Pharmaceuticals had 1 more articles in the media than Codex DNA. MarketBeat recorded 1 mentions for EyePoint Pharmaceuticals and 0 mentions for Codex DNA. EyePoint Pharmaceuticals' average media sentiment score of 0.72 beat Codex DNA's score of 0.05 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
EyePoint Pharmaceuticals Positive
Codex DNA Neutral

Codex DNA has a net margin of 0.00% compared to EyePoint Pharmaceuticals' net margin of -167.42%. Codex DNA's return on equity of 0.00% beat EyePoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
EyePoint Pharmaceuticals -167.42% -64.16% -34.22%
Codex DNA N/A N/A N/A

EyePoint Pharmaceuticals presently has a consensus price target of $22.38, indicating a potential upside of 53.89%. Codex DNA has a consensus price target of $23.19, indicating a potential upside of 261.78%. Given Codex DNA's higher possible upside, analysts clearly believe Codex DNA is more favorable than EyePoint Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EyePoint Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Codex DNA
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

EyePoint Pharmaceuticals beats Codex DNA on 8 of the 12 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Codex DNA (NASDAQ:DNAY) vs. Its Competitors

TypeCodex DNAAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$187.86M$8.21B$4.86B$7.69B
Dividend YieldN/A0.29%2.04%2.59%
P/E RatioN/A11.2322.9723.31
Price / SalesN/A55.132,379.89253.60
Price / CashN/A40.4561.74204.42
Price / Book1.8313.796.006.31
Net IncomeN/A$332.54M$95.76M$154.30M
7 Day Performance-6.29%-4.84%-4.25%-2.86%
1 Month Performance-38.54%-16.26%-13.75%-11.11%
1 Year PerformanceN/A27.89%7.14%25.46%

Codex DNA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAUT
Nautilus Biotechnology
2.1331 of 5 stars
$4.95
-2.2%
$11.50
-132.3%
N/A$614.63MN/A0.0082
EYPT
EyePoint Pharmaceuticals
2.3264 of 5 stars
$14.54
-0.1%
$22.38
-53.9%
-71.9%$492.82M$34.44M-5.82100
AKYA
Akoya Biosciences
1.9931 of 5 stars
$12.74
-2.6%
$25.50
-100.2%
N/A$474.03M$42.44M0.00169Short Interest ↓
Gap Down
RPID
Rapid Micro Biosystems
1.6399 of 5 stars
$9.94
-18.4%
$27.33
-175.0%
N/A$411.05M$16.08M0.002,021
FLDM
Fluidigm
2.0333 of 5 stars
$4.25
-0.9%
$7.00
-64.7%
-30.8%$325.07M$138.14M-4.72627
ISO
IsoPlexis
1.7 of 5 stars
$8.02
-29.3%
$20.00
-149.4%
N/A$312.42MN/A0.002,021
AXDX
Accelerate Diagnostics
2.7314 of 5 stars
$4.77
-4.2%
$9.00
-88.7%
-36.7%$293.35M$11.16M-3.82224
HBIO
Harvard Bioscience
2.3948 of 5 stars
$6.64
-0.6%
$9.00
-35.5%
+69.4%$270.99M$102.10M-132.80444
TLIS
Talis Biomedical
2.2115 of 5 stars
$4.86
-4.1%
$12.00
-146.9%
N/A$127.77M$10.94M0.00135
PRPO
Precipio
2.0198 of 5 stars
$1.80
-2.2%
$7.00
-288.9%
-24.1%$40.87M$6.09M0.0056
ASTC
Astrotech
1.1981 of 5 stars
$0.73
-2.7%
N/A-59.5%$36.14M$330K0.0027
SQL
SeqLL
0 of 5 stars
$2.52
-5.6%
N/AN/A$29.95M$330K0.00N/ANegative News
This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.